Browsing Tag
Boston
56 posts
Tango Therapeutics (NASDAQ: TNGX) jumps 11% into May 11 earnings and pivotal pancreatic cancer data
Tango Therapeutics is up 22-fold from $1.04 in twelve months. The May 11 earnings print decides whether vopimetostat justifies the run or breaks it.
Seaport Therapeutics seeks $212m IPO as neuropsychiatry biotech window reopens
Seaport’s IPO tests biotech appetite before key depression data. Here’s why SPTX, PureTech, and psychiatry investors are watching.
Mauna Kea Technologies FY2025 results show why ALMKT is no longer just a restructuring story
Mauna Kea Technologies says FY2025 reset its balance sheet and reignited growth. Read what the debt cut, U.S. sales surge, and 2026 outlook mean.
Why Lilly’s $3.25bn Kelonia acquisition signals a manufacturing shift across the entire CAR-T landscape
Eli Lilly agrees to acquire Kelonia Therapeutics for up to $7B. What the iGPS in vivo CAR-T platform means for oncology and LLY investors. Read the analysis.
NHS England commits £237m to expand Community Diagnostic Centres as government targets record diagnostic output in 2026
The UK government commits £237 million to expand NHS Community Diagnostic Centres across England. What the investment means for waiting lists, care access, and NHS strategy. Read more.
Aramark (NYSE: ARMK) wins Suffolk University dining deal as campus hospitality becomes a growth lever
Aramark’s Suffolk University win is more than a campus dining deal. Read how it could shape growth, student experience, and investor sentiment.
Simon Property Group (NYSE: SPG) announces landmark redevelopment of Copley Place to reinforce Boston luxury retail positioning
Simon Property Group Inc. redevelops Copley Place to anchor Boston luxury retail. Find out what this means for SPG and high-end malls.
U.S. declares multi-state emergencies amid widespread snowfall and freezing rain
Power outages, flight cancellations, and emergency declarations sweep across 20 U.S. states as a powerful winter storm paralyzes major cities and services.
Can Thermo Fisher’s new molecular test transform lung transplant care with faster rejection detection?
Discover how Thermo Fisher’s new AI-based MMDx Lung test improves early detection of lung transplant rejection and reshapes transplant diagnostics.
ExQor Technologies moves closer to clinical trials with brain regenerative medicine for Alzheimer’s disease
ExQor Technologies advances toward clinical trials with a brain regenerative platform that could reverse Alzheimer’s damage and transform dementia care.